Global Cardio-Oncology Summit 2016

Margot Davis, MD

Cardiologist, Vancouver General Hospital and St. Paul's Hospital; Clinical Assistant Professor and Director, UBC Cardio-Oncology Program, The University of British Columbia, Vancouver, British Columbia, Canada

founder

Margot Davis is a cardiologist at Vancouver General Hospital and St. Paul’s Hospital, a Clinical Assistant Professor at the University of British Columbia, and Director of the UBC Cardiology-Oncology Program. She obtained her Bachelor of Science in Physiology at McGill University before attending medical school at the University of British Columbia.

Read More...

She stayed at UBC for her Internal Medicine residency and Cardiology fellowship. She then completed fellowships in Advanced Heart Failure & Transplant Cardiology and Cardio-Oncology & Cardiac Amyloidosis at Stanford University School of Medicine. She is a candidate for a Masters of Science in clinical epidemiology at the Harvard School of Public Health. Her research interests are focused on the prevention, diagnosis, and management of heart disease related to cancer therapy and the epidemiology of heart disease in cancer survivors. She also has interests in cardiac amyloidosis and advanced heart failure.

Susan Dent, MD

President, Canadian Cardiac Oncology Network; Medical Oncologist, The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada

founder

Dr. Dent is a Medical Oncologist at The Ottawa Hospital Cancer Centre and Associate Professor in the Department of Medicine at the University of Ottawa.  She obtained her MD at McMaster University and completed her postgraduate training in Internal Medicine at the University of Ottawa. She continued her training in Medical Oncology in Ottawa, followed by a fellowship year in Clinical Research with the National Cancer Institute of Canada Clinical Trials Group.

Read More...

She is the research lead for the breast disease site group at the Ottawa Hospital Cancer Centre, and a member of the IND working group for the Breast Cancer Disease Site Committee of the National Cancer Institute for Canada Clinical Trials Group. Her areas of research interest include breast cancer, and treatment related toxicities with a particular interest in cardiotoxicity. She is the founder of the Ottawa Cardiac Oncology Program as well as the Canadian Cardiac Oncology Network, organizations dedicated to improving our understanding of how cancer treatments impact cardiovascular health with the ultimate goal of preventing cardiotoxicity.

Barbara Fitzgerald, RN, MScN

Chief Nursing Officer, Head of Interprofessional Practice and Patient Experience, BC Children’s Hospital, BC Women’s Hospital and Health Centre and Sunny Hill Health Centre for Children, Vancouver, British Columbia, Canada

founder

Barbara has over 25 years of acquired experience in nursing, health care services and leadership. Her experience in the health care system has included significant outcomes related to advanced practice, inter-professional collaboration and education, culture transformation and innovative models of care.

Daniel Lenihan, MD

President, International CardiOncology Society - North America; Professor of Medicine; Director, Clinical Research Program, Vanderbilt Heart and Vascular Institute, Nashville, Tennessee, USA

founder

Dr. Lenihan, has been active in clinical research in cardiology, and specifically in heart failure, for nearly 20 years. The main focus of these efforts have included hemodynamic assessments, angiogenic growth factor response, novel cardiac biomarkers as well as optimal methods to prevent or detect heart failure at the earliest stage possible in patients undergoing treatment for cancer.

Read More...

His current projects include early phase clinical trials in heart failure, including the recently presented Phase 1 trial of GGF2 in cooperation with Acorda, Inc. As the Director of Clinical Research in the Division of Cardiovascular Medicine, Dr Lenihan is managing over 100 clinical trials in conjunction with all of VHVI faculty and continues to enhance and foster collaboration among a host of colleagues both internally and throughout the world. He is the current president (US/Canada) of the International CardiOncology Society, a professional association whose primary goal is to eliminate cardiac disease as a barrier to effective cancer therapy.

Alexander Lyon, MA BM BCh PhD FRCP

British Heart Failure Foundation Senior Lecturer in Cardiology, Imperial College London; Consultant Cardiologist, Royal Brompton Hospital, London, England, UK. President of the British Cardio-Oncology Society. Clinical Lead for Cardio-Oncology service, Royal Brompton Hospital, London, England

founder

Dr. Alexander Lyon is a British Heart Foundation Senior Lecturer in Cardiology at Imperial College London and a Consultant Cardiologist at the Royal Brompton Hospital. He studied medicine at Oxford University where he gained a first class degree, and studied for his PhD thesis in myocardial gene therapy at Imperial College London.

Read More...

He continued his gene therapy research during a postdoctoral research year in the laboratory of Roger Hajjar at Mount Sinai Hospital in New York. His clinical interests are in the field of heart failure, cardio-oncology and Takotsubo syndrome, and he is the theme leader for heart failure research in the NIHR-funded Biomedical Research Unit at the Royal Brompton Hospital. He is the clinical lead for the new Cardio-Oncology service at the Royal Brompton hospital, specialising in surveillance and cardioprotection from modern cancer drugs, risk stratification and treatment of all cardiac complications of cancer treatment. He is the president of the British Cardio-Oncology Society and a member of the European Society of Cardiology Taskforce on Cardio-Oncology. He is the clinical advisor to the british cancer patient charity Macmillan Cancer and helped to write the first patient information leaflet – Heart health for Cancer Patients. He is the UK national lead investigator for two gene therapy trials for chronic heart failure (CUPID2 and SERCA-LVAD), and is the heart failure lead for the RDN-HFpEF study assessing the role of renal sympathetic denervation for individuals with heart failure with preserved ejection fraction. He is leading both a laboratory research programme understanding the influence of stress and high catecholamine levels upon myocardial function, and he is coordinating both a national and European strategy to advance knowledge and improve care for individuals with Takotsubo syndrome. He runs a specialist clinic for patients with Takotsubo syndrome focussing on risk prediction and management of refractory symptoms.

Christine Simmons, MD

Co-Chair, GCOS 2016; Medical Oncologist, BC Cancer Agency, Vancouver, British Columbia, Canada

founder

Dr. Christine Simmons is a Medical Oncologist at the BCCA Vancouver. She completed her residency training in Toronto, and completed a fellowship in Locally Advanced Breast Cancer at Princess Margaret Hospital in Toronto. She also completed a Master’s in Clinical Epidemiology at University of Toronto. She is a Clinical Assistant Professor at the University of British Columbia in the Faculty of Medicine.

Read More...

She is past Chair of the Locally Advanced Breast Cancer Canadian National Consensus group, and has a strong research interest in this area. In July 2014 she took on the role of Clinical Skills Course Director in the undergraduate medical program at UBC.

Jeffrey Sulpher, MD

Medical Oncologist, The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada

founder

Dr. Jeffrey Sulpher received his BSc.(Hons.) in Biopharmaceutical Sciences from the University of Ottawa in 2003, and his M.D. from Queen's University in 2008.  He went on to complete his internal medicine and medical oncology residencies at the University of Ottawa.  He is currently a cardiac oncology fellow at the Ottawa Hospital Cancer Centre.

Read More...

His current research projects include the investigation of biomarkers for identification of patients at risk of treatment-induced cardiotoxicity, as well as a national physician's survey exploring issues surrounding cardiac oncology in Canada.

Sean A. Virani, MD, MSc, MPH, FRCPC

Co-Chair, GCOS 2016; Associate Professor of Medicine, University of British Columbia; Provincial Heart Failure Lead, Cardiac Services BC, Vancouver, British Columbia, Canada

founder

Dr. Virani is a key opinion leader for heart failure in Canada. He is founding Director of the Heart Failure Program at Vancouver General Hospital, Regional Director of Heart Failure Services for Vancouver Coastal Health/Providence Health Care, Heart Failure Physician Lead at Cardiac Services BC and Clinical Associate Professor of Medicine at the University of British Columbia.

Read More...

He completed his internal medicine and cardiology training at UBC before embarking on a sub-specialization in heart failure and cardiac transplantation at Stanford University. He also has a Master’s degree in Public Health from Columbia University with a focus on healthcare management. His professional interests include public policy related to health care delivery with specific reference to healthcare systems redesign and quality in the Canadian context. Dr. Virani has authored a number of papers on chronic and acute decompensated heart failure and is a principal investigator on numerous research trials. He holds peer reviewed grant funding as a principal or co-investigator in excess of $1 million. He serves on the Provincial Advisory Committee for Cardiac Health, the executive of the Canadian Heart Failure Society, the Canadian Heart Failure Guidelines Committee and Co-Chairs British Columbia’s Specialist Services Committee.